Loading...
Please wait, while we are loading the content...
Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
| Content Provider | Scilit |
|---|---|
| Author | Ottmann, Oliver G. Wassmann, Barbara |
| Copyright Year | 2005 |
| Description | Philadelphia chromosome positive $(Ph^{+}$) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL. Until recently, conventional chemotherapy programs that have been effective in other precursor B-cell ALL cases have been unable to cure patients with this diagnosis. Allogeneic stem cell transplantation early in first remission has been the recommended therapy. The availability of imatinib mesylate and other tyrosine kinase inhibitors and small molecules that affect the BCR/ABL signaling pathways may be changing the treatment paradigm and the prognosis for these patients. The results from clinical trials using imatinib in the frontline setting and in relapsed patients as well as preliminary experience treating imatinib-resistant $Ph^{+}$ ALL will be described. |
| Related Links | http://asheducationbook.hematologylibrary.org/content/2005/1/118.full.pdf |
| Ending Page | 122 |
| Page Count | 5 |
| Starting Page | 118 |
| DOI | 10.1182/asheducation-2005.1.118 |
| Journal | Hematology |
| Issue Number | 1 |
| Volume Number | 2005 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2005-01-01 |
| Access Restriction | Open |
| Subject Keyword | Cell Tissue Engineering Treatment Adults Sup Philadelphia Leukemia Chromosome Imatinib Acute Lymphoblastic Journal: Hematology (Vol- 26, Issue- 1) |
| Content Type | Text |
| Resource Type | Article |